You are here: Industry Insights > BMS

News List

BMS Names EVP, CSO contractpharma
March 10, 2017
Lynch brings 30 years of medical, management and leadership experience
The 5 Drug Giants That Could Snap Up a Struggling Bristol-Myers Squibb BioSpace.com
March 06, 2017
Speculation on what company will make a bid for beleaguered Bristol-Myers Squibb (BMS) has ramped up since billionaire activist investor Carl Icahn acquired an undisclosed number of shares based on takeover rumors.
BMS, GRAIL in Precision Medicine Pact contractpharma
March 02, 2017
BMS investment aims to advance pipeline with highly sensitive blood tests that detect cancer early
Bristol-Myers Squibb expands International Immuno-Oncology Network (II-ON) worldpharmanews
February 28, 2017
Bristol-Myers Squibb Company (NYSE:BMY) today announced that Columbia University Medical Center and Peter MacCallum Cancer Centre (Peter Mac) have joined the International Immuno-Oncology Network (II-ON).
Allergan CEO says "everybody" likely looking at Bristol-Myers Squibb: report firstwordpharma
February 24, 2017
Allergan CEO Brent Saunders suggested that a number of companies will be looking at Bristol-Myers Squibb as a potential takeover target given its share price decline over the past six months, Bloomberg reported Thursday.
Bristol-Myers Squibb Seen as Takeover Bait firstwordpharma
February 15, 2017
People close to the matter revealed that Bristol-Myers Squibb is viewed as a takeover target by multiple drugmakers, StreetInsider reported Tuesday.
BMS receives $625 million patent settlement boost from Merck pharmafile
January 24, 2017
Bristol-Myers Squibb were in desperate need of releasing good news after the brief announcement that it would no longer be pursuing an accelerated regulatory pathway for Opdivo with Yervoy...
Merck agrees to resolve Keytruda patent infringement litigation pharmaceutical-technology
January 24, 2017
US-based Merck and associated affiliates have entered an agreement with Bristol-Myers Squibb and Ono Pharmaceutical, to resolve Keytruda (pembrolizumab) patent litigation.
BMS, Ono Pharma and Merck resolve PD-1 antibody patent litigation cphi-online
January 24, 2017
Merck to pay BMS and Ono royalties on global sales of Keytruda through 2026, and lump-sum payment of $625 million.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page